Abstract
In South Korea, despite the implementation of a universal single-dose vaccination program for children aged 12–15 months in 2005, the varicella incidence rate remains significant. Prior case-control studies have reported that currently used varicella vaccines are extremely inefficacious. We estimated vaccine effectiveness (VE) by fitting a dynamic transmission model to age-specific varicella incidence data from 2007 to 2015 and available vaccine coverage data. The initial vaccine efficacy and primary failure rates were estimated to be 61.1% and 38.9%, respectively. The average duration of protection was 21.4 years. The mean VE [(1-relative risk) %] for the simulated data of 2004–2014 birth cohorts decreased from 59.8% to 50.7% over 9 years. This mathematical modeling study demonstrated that the single-dose vaccine exhibits moderate effectiveness, and a high proportion of primary failure could be a main cause of breakthrough infections. Therefore, a two-dose vaccination strategy should be considered.
Original language | English |
---|---|
Article number | 2085468 |
Journal | Human Vaccines and Immunotherapeutics |
Volume | 18 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Funding Information:This work was supported by the National Research Foundation of Korea (NRF) under Grant [2018R1A2B6006178]; and Korea Government (MSIT) under Grant [NRF-2020R1A2C1A01010775].
Publisher Copyright:
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Pharmacology